Breakthroughs & big backing: key stocks surging today

Good day, 360! Here are some of our top movers today. And don’t forget…👉MEGA deal ENDS TONIGHT on JW’s Weekly Wiretaps [new].  Only $97 for a full year… every year.  Subscribe Here. 

Ending in just:

FOCUS LIST🔎

SLQT - Up over 29% in the pre-market after announcing  $350 Million Strategic Investment from Bain Capital, Morgan Stanley Private Credit and Newlight Partners

OCEA - 2nd day, up over 50% in pre after yesterday announcing breakthrough findings in EGFR-Mutant Lung Cancer and plans for FDA alignment on next-stage development  

IINN - Up over 24% in pre after announcing positive results of above 95% for preventing bloodstream infections

HOTLIST🔥

SLQT - Up over 29% in the pre-market after announcing  $350 Million Strategic Investment from Bain Capital, Morgan Stanley Private Credit and Newlight Partners

SelectQuote Inc. (SLQT) operates a technology-enabled, direct-to-consumer distribution platform that sells insurance policies and healthcare services in the United States.

In the after-hours yesterday, the company announced that it had signed a $350 million strategic investment from funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners.

This investment will allow the Company to recapitalize its balance sheet, to lower its annual cash debt service, and to provide liquidity and increase operating flexibility to fund growth initiatives. 

The Company’s successful renegotiation of its Senior Secured Credit Facility provides a lower interest rate on the remaining balance.

This investment will accelerate the Company’s effort to optimize its capital structure as it continues to explore accretive, strategic solutions with its insurance carrier partners and to grow its rapidly expanding healthcare services business.

Shares of SLQT traded up over 29% in the pre-market in reaction to the news.

The $5.61 area acted as support in the pre-market and will be an  important level to watch. Above it, targets to the upside are $5.80, $6 and then the pre-market high at $6.20. Beyond that, $7, $7.50 and $8 come into play.

Below $5.61, targets to the downside are $5.51, $5 and then a gap fill at $4.38. 

OCEA - 2nd day, up over 50% in pre after yesterday announcing breakthrough findings in EGFR-Mutant Lung Cancer and plans for FDA alignment on next-stage development 

Ocean Biomedical, Inc. (OCEA) is a biopharmaceutical company that focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases.

In the pre-market yesterday, the company announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). 

Specifically, they demonstrate that Ocean’s immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper’s findings demonstrate that its proprietary cancer immunotherapy candidates have a remarkable ability to restore treatment sensitivity following development of osimertinib resistance.

This breakthrough offers a potential paradigm shift in the treatment of Epidermal Growth Factor Receptor (EGFR)-mutant NSCLC and could expand treatment options for patients whose tumors are no longer responding to tyrosine kinase inhibitors.

After selling off from the open yesterday, OCEA found buyers in the after-hours and is gapping up over 50% in the pre-market in reaction to the news.

The $0.24 area acted as resistance in the pre-market and will be an important level to watch.

Above it, targets to the upside are $0.26 and then the pre-market high at $0.2821. Beyond that, $0.37, $0.45 and $0.60 come into play.

Below $0.24, targets to the downside are $0.22, $0.20, $0.18, $0.16, $0.1480 and then $0.1127. 

🏇 Pick Your Pony 🏇

Or Bet on BOTH Top Picks of the Week

Weekly Wiretaps with JW

(launch deal ENDS TONIGHT) 

OR

Bullseye Trades with Jeff

OR call Davis for the best deal when you double up!

1-443-269-8824 / Davis@ragingbull.com

IINN - Up over 24% in pre after announcing positive results of above 95% for preventing bloodstream infections

Inspira Technologies Oxy B.H.N. Ltd. (IINN) is a specialty medical device company that engages in the research, development, manufacture, and marketing of proprietary life support technology for the treatment of acute respiratory failure.

In the pre-market this morning, the company announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections.

In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over a 24-hour period. The technology, which uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.

Testing was conducted following adjusted standardized protocols, including the AATCC TM100 standard for antimicrobial performance, with results showing consistent bacterial reduction under active patches compared to controls.

Shares of IINN traded up over 24% in the pre-market in  reaction to the news.

The first target for bulls is the psychological $1 level and then the pre-market high at $1.11. Beyond that, $1.20, $1.40, $1.50 and $1.60 come into play.

Below $1, targets to the downside are $0.90 and then a gap fill at $0.8490. 

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed 🚀past the MOON 🌝.  Text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.